Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
The most common (≥10%) injection-site reaction was pain (>37%); the most common (≥10%) solicited systemic adverse reactions were headache (>15%), fatigue (>15%) and myalgia (>11%).[1]
Adapted from the FDA Package Insert.